Administration of gallium nitrate by continuous infusion: lack of chronic nephrotoxicity confirmed by studies of enzymuria and beta 2-microglobulinuria.
Enzymuria and beta 2-microglobulinuria are sensitive markers of injury to renal tubular cells. We evaluated these markers in 41 patients with advanced malignant lymphoma who received gallium nitrate administered as a continuous infusion during a recent phase I-II study. In contrast to our findings with cisplatin, we observed no significant increase in enzyme excretion or beta 2-microglobulinuria in these patients even after long-term treatment. Our results indicate that gallium nitrate administered by infusion does not produce cumulative renal tubular toxicity.
D000118:Acetylglucosaminidase / Q000652:urine; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005708:Gallium / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007931:Leucyl Aminopeptidase / Q000652:urine; D001613:beta 2-Microglobulin / Q000652:urine*
D000970:Antineoplastic Agents; D001613:beta 2-Microglobulin; D005708:Gallium; D000118:Acetylglucosaminidase; D007931:Leucyl Aminopeptidase; C027235:gallium nitrate